Novartis therapy for infant muscle-wasting disease — potentially carrying a record $2 million price tag — is about to hit market

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 97%

Colombia Noticias Noticias

Colombia Últimas Noticias,Colombia Titulares

A new treatment for an infant muscle-wasting disease is about to go on sale at a potential cost of $2 million, a record price tag likely to fuel the continuing scrutiny of how companies price their drugs and how insurers pay for them.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

 /  🏆 3. in CO
 

Gracias por tu comentario. Tu comentario será publicado después de ser revisado.

Permanent fixes = overpriced. Temporary relief with side effects = underpriced. Dont blame big Pharma. Dont blame insurance companies. Blame every person who pays these companies & says 'that's just how it is.' Everyone is free to make their own choices, except those babies.

Colombia Últimas Noticias, Colombia Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

A $2 Million Drug Is About to Hit the MarketA new treatment for an infant muscle-wasting disease is about to go on sale at a potential cost of $2 million, a record price tag likely to fuel the continuing scrutiny of how companies price drugs and how insurers pay for it. This should be classified as a human rights violation. I'll take two, please. I don't believe $2 Million is justified. It is Medical Extortion, nothing more!
Fuente: WSJ - 🏆 98. / 63 Leer más »